Rosalind McAlpine and Karel Kieslich summarise a recent systematic review which focuses on the rapid anti-suicidal ideation effect of ketamine.
[read the full story...]
Alexandra Pike, Alexis An Yee Low and Jonathan Roiser critically appraise a recent n-of-1 study on ‘brain pacemakers for depression’, which received extensive press coverage earlier this month. The case study looks at deep brain stimulation (closed-loop neuromodulation) in an individual with treatment-resistant depression.
[read the full story...]
Anya Borissova summarises a recent randomised placebo-controlled trial that evaluated ketamine metabolites, clinical response, and gamma power for major depression.
[read the full story...]
James Rucker and Sameer Jauhar summarise a recent RCT on the effectiveness of psilocybin assisted therapy versus escitalopram assisted therapy for major depressive disorder.
[read the full story...]
In her debut blog, Harmony Jiang reviews a recent qualitative study exploring patients’ experience and response to ketamine treatment for depression.
[read the full story...]
Anya Borissova summarises the therapeutic mechanisms of psilocybin in treatment-resistant depression and changes noticed in the amygdala and prefrontal cortex during emotional processing.
[read the full story...]
Pascal Immanuel Michael summarises a recent RCT, which looks at how a single dose of the psychedelic Ayahuasca may help people with severe depression who have not benefited from more traditional treatment.
[read the full story...]
Jodi Rintelman writes her debut elf blog on the first randomised controlled trial on the efficacy and safety of intranasal esketamine as an adjunctive treatment to antidepressants for treatment-resistant depression.
[read the full story...]
Jessica Bone reports on a recent cross-sectional study that looks at the clinical correlates of augmentation/combination treatment strategies in major depressive disorder.
[read the full story...]
Our #EvidenceLive team of bloggers report on a recent feasibility study of psilocybin for the treatment of refractory depression.
[read the full story...]
